Pumactant in the prevention of postoperative adhesions: A randomized trial

Abstract Background Postoperative intraperitoneal adhesions are a considerable source of morbidity. Supplementing compromised endogenous intraperitoneal phospholipids can reduce postoperative adhesions. A randomised, controlled, parallel group study was performed to evaluate the efficacy, safety and...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of surgical research 2012-12, Vol.178 (2), p.677-684
Main Authors: Shimi, Sami M., MD, FRCS, Loudon, Malcolm A., MD, FRCS
Format: Article
Language:English
Subjects:
Abdominal surgery
Adult
Aged
Colectomy
Colostomy
Double-Blind Method
Female
Humans
Ileostomy
Male
Middle Aged
Postoperative adhesions
Postoperative Complications - prevention & control
Pulmonary Surfactants - therapeutic use
Pumactant
Surgery
Tissue Adhesions - prevention & control
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Postoperative intraperitoneal adhesions are a considerable source of morbidity. Supplementing compromised endogenous intraperitoneal phospholipids can reduce postoperative adhesions. A randomised, controlled, parallel group study was performed to evaluate the efficacy, safety and tolerability of pumactant in the prevention of peritoneal adhesions after abdominal colorectal surgery. Materials and methods A total of 134 patients undergoing partial colectomy and colostomy or ileostomy were randomized to receive either 240 mg of pumactant or placebo (carbon dioxide) sprayed into the peritoneal cavity. The outcome measures were efficacy (adhesion incidence and extent and severity at the second surgery) and the safety of pumactant in the peritoneal cavity after abdominal surgery. Results The mean adhesion score increased from surgery 1 to surgery 2 in the pumactant group and decreased in the placebo group, and the incidence and extent of adhesions increased in both groups. A total of 2149 adverse events were reported, of which 158 were serious. The overall adverse event profile for the two groups (pumactant and placebo) was very similar. Conclusions Although pumactant is relatively safe by the intraperitoneal route, 240 mg powdered pumactant is not effective in reducing postoperative peritoneal adhesions.
ISSN:0022-4804
1095-8673
DOI:10.1016/j.jss.2012.06.060